Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

Sanofi said it agreed to buy U.K. vaccine developer Vicebio for up to $1.6 billion, adding vaccine candidates for respiratory syncytial virus and human metapneumovirus to its pipeline.

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...